Check the vial, not the box
The interval between manufacture and analysis is the most under-read figure on the page, and the one most likely to matter by the time a vial is opened.
Certificates of analysis
Page 35 of 51 of this archive, newest first.
Australia health authority warns on falsified semaglutide pens
Reported from the analysis, not from a warning notice.
The reproducible spectrum: the single most useful thing a report can carry
None of what a checkable identity statement requires is commercially sensitive, and all of it is known to whoever produced the document.
VendorInvestigate result on a Guangzhou retatrutide lot lands 3.9 points above the supplier’s stated figure
The result is unremarkable. What the report states alongside it is not.
The reviewer, the approver, and why regulated documents carry two names
What the Journal asks when a document arrives unsigned, and what the answers have been.
What changed at SWB in November, and what the company says prompted it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Everything a buyer assumes has been checked, ranked by whether it has
A purity figure is silent on peptide content, on water, on counter-ion, on sterility, on endotoxin and on stability. Each of those silences has a price attached.
SGN names the synthesis and fill sites behind its catalogue
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
VendorInvestigate result on a Nantong cagrilintide lot lands 4.4 points above the supplier’s stated figure
The report states the gradient, the wavelength and the integration threshold, which is more than most.
Poland health authority warns on falsified semaglutide pens
Reported from the analysis, not from a warning notice.
Independent analysis puts a Homopeptide tirzepatide lot at 99.3%, against 95.3% on the certificate
The result is unremarkable. What the report states alongside it is not.
QSC names the synthesis and fill sites behind its catalogue
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What changed at WXT in November, and what the company says prompted it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Independent analysis puts a SGN exenatide lot at 96.4%, against 94.7% on the certificate
The report states the gradient, the wavelength and the integration threshold, which is more than most.
What changed at WWB in November, and what the company says prompted it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What Janoshik would need in order to certify sterility, and why it does not
The absence of microbiological capability in this market is a commercial fact with a straightforward explanation, and it is worth understanding before blaming anybody for it.
The retest date and the expiry date are not the same document
We asked twenty companies three questions about stability data and print every answer, refusal and non-response.
Independent analysis puts a QST dulaglutide lot at 95.3%, against 91.7% on the certificate
The result is unremarkable. What the report states alongside it is not.
The degradation product that elutes underneath the parent peak
An isoaspartate rearrangement changes the molecule and not the mass. A method that confirms identity by molecular weight alone will report it as the parent compound.
Independent analysis puts a TFC dulaglutide lot at 95.8%, against 95.1% on the certificate
The report states the gradient, the wavelength and the integration threshold, which is more than most.